Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

In This Article:

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Adaptive Biotechnologies is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 8.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

According to our latest data, ADPT has moved about 15.4% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.8%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.

Another stock in the Medical sector, Bio-Rad Laboratories (BIO), has outperformed the sector so far this year. The stock's year-to-date return is 4.9%.

In Bio-Rad Laboratories' case, the consensus EPS estimate for the current year increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 512 individual companies and currently sits at #56 in the Zacks Industry Rank. On average, this group has lost an average of 13.6% so far this year, meaning that ADPT is performing better in terms of year-to-date returns.

In contrast, Bio-Rad Laboratories falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #77. Since the beginning of the year, the industry has moved +14.1%.

Adaptive Biotechnologies and Bio-Rad Laboratories could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.


Waiting for permission
Allow microphone access to enable voice search

Try again.